Incyte INCY announced that the European Commission (EC) approved the novel cream formulation of JAK1/JAK2 inhibitor ruxolitinib (15 mg/g), Opzelura, for the treatment of non-segmental vitiligo with ...

US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo. The double ...

Segmented email campaigns have, on average, significantly higher open and click rates—and significantly lower bounce, abuse, and unsubscribe rates—than non-segmented campaigns, according to recent ...

LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura ® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with ...

This article intends to cover two aspects of non-segmented negative sense RNA viruses. In the initial section, the strategy employed by these viruses to replicate their genomes is discussed. This ...